Cargando…
Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch(®) capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus
BACKGROUND: Intractable pruritus in hemodialysis patients can significantly decrease their quality of life and is also associated with poor vital prognosis. Although combined multiple causes of intractable pruritus in these patients have been identified, no existing treatments are proven to be suffi...
Autores principales: | Kozono, Hideki, Yoshitani, Hiroshi, Nakano, Ryoko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774492/ https://www.ncbi.nlm.nih.gov/pubmed/29391822 http://dx.doi.org/10.2147/IJNRD.S145720 |
Ejemplares similares
-
Post-Marketing Surveillance Study of the Safety and Efficacy of Nalfurafine (Capsules 2.5 μg, Oral Dispersing Tablets 2.5 μg) in 1186 Patients with Chronic Liver Disease and Intractable Pruritus
por: Yoshitani, Hiroshi, et al.
Publicado: (2022) -
Nalfurafine hydrochloride to treat pruritus: a review
por: Inui, Shigeki
Publicado: (2015) -
Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride
por: Yoshikawa, Shuhei, et al.
Publicado: (2021) -
Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients
por: Zhang, Ping, et al.
Publicado: (2023) -
Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease
por: Kawano, Tadamichi, et al.
Publicado: (2022)